Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
about
Vaccines for preventing herpes zoster in older adultsVaccinology in the third millennium: scientific and social challengesLocal innate immune responses in the vaccine adjuvant-injected muscleImmunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled studyA phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.Varicella zoster virus infection.Live attenuated herpes zoster vaccine for HIV-infected adults.The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.The herpes zoster subunit vaccine.Aging of the immune system: Focus on inflammation and vaccination.Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.Vaccine profile of herpes zoster (HZ/su) subunit vaccine.A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits.Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Vaccines for the elderly: current use and future challenges.Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged ≥50 Years.Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Breadth and functionality of varicella zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans.Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profileEfficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
P2860
Q24186050-783F2182-258B-4A85-8059-48EBFE50ECC9Q24261399-8A736F00-8823-4D36-AA2B-6EDA637FC0DEQ28079872-C793606C-C1D7-4D0F-8BCE-1B60983B00A1Q33724403-0F809979-D166-45FE-8CAD-55BA2B6E6B77Q33746872-4382EE9E-EE83-40FB-892E-993FFDDC93E4Q34446365-59F3D633-9B07-432D-8B14-2F0BD184645CQ35081168-E7CBC2F7-AD6C-455B-AC5B-4E8232F110ABQ35887417-0EB75632-2F19-41E3-8680-E1C6867161CAQ36024466-76CD857A-9B07-45F9-8161-4C59BBE77F92Q37713779-DB32E1A9-39FB-4C8E-AF5B-09E819D32A4EQ37738789-683DD349-478B-4B86-90D1-9E7318BF0FC5Q38575356-512A3AFE-9A29-4314-95A4-942043E3BBF3Q38682515-8258D92E-1DB0-47E1-8D38-8E991FA7C1EDQ38728931-6F47D987-D1E7-48E1-9E9B-3A828E3E5C56Q38946555-C3F3619A-3848-4327-8EF1-C6A45386829BQ40064119-BDA242EA-A5CE-4188-8B8B-5EF1216CCC4CQ40208840-D06D18ED-D1C7-4467-AABB-64A6CE47B3D3Q40234780-08A6B7DB-1D53-471E-94A1-59AE5E117047Q40757793-06221CDB-5179-420E-B325-4ADB488ED7B2Q40876878-922AE484-8093-4DCF-9619-C424D245CDDEQ46892547-91DBEDFB-C03D-4D05-B9C8-713382DA1E92Q47547388-C5E92D47-BB05-4662-BB6A-C88A9220EF23Q52727148-581277E7-B427-417F-8423-99DEDADAF14EQ52801394-B6D0CA7B-46B1-4C6C-9292-1CDB929E883CQ54216748-220960A1-C15F-49E7-9027-3EA69B354F4EQ54260853-051DCE50-AC6D-4B58-829B-8B66378CD895Q56888201-677F9565-E4C9-4B2E-975D-D20C8555929BQ58553251-62072FF8-8E7F-472A-B58B-75C4DD4D0FD7
P2860
Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@en
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@nl
type
label
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@en
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@nl
prefLabel
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@en
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@nl
P2093
P2860
P356
P1476
Safety and immunogenicity of a ...... r in adults >=50 years of age.
@en
P2093
Edouard Ledent
Harry Collins
Johann F Mols
José M Bayas
Maria Luisa Rodriguez de la Pinta
Roman Chlibek
Thomas C Heineman
P2860
P304
P356
10.1093/INFDIS/JIT365
P407
P577
2013-07-31T00:00:00Z